Log in
NYSE:ADCT

ADC Therapeutics News Headlines

$35.69
-0.05 (-0.14 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$34.89
Now: $35.69
$36.14
50-Day Range
$25.26
MA: $31.49
$36.17
52-Week Range
$25.10
Now: $35.69
$56.59
Volume73,551 shs
Average Volume247,697 shs
Market Capitalization$2.46 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

ADC Therapeutics (NYSE ADCT) News Headlines Today

Source:
SourceHeadline
ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of "Buy" from BrokeragesADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of "Buy" from Brokerages
americanbankingnews.com - November 23 at 7:28 AM
ADC Therapeutics (NYSE:ADCT) Trading 6.3% Higher ADC Therapeutics (NYSE:ADCT) Trading 6.3% Higher
americanbankingnews.com - November 20 at 6:51 PM
FDA accepts ADC Therapeutics lonca US application for a type of blood cancerFDA accepts ADC Therapeutics' lonca US application for a type of blood cancer
seekingalpha.com - November 20 at 7:55 AM
ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
finance.yahoo.com - November 20 at 7:55 AM
Is ADC Therapeutics (NYSE:ADCT) A Risky Investment?Is ADC Therapeutics (NYSE:ADCT) A Risky Investment?
finance.yahoo.com - November 18 at 7:39 AM
ADC Therapeutics (ADCT) CEO Chris Martin on Q3 2020 Results - Earnings Call TranscriptADC Therapeutics' (ADCT) CEO Chris Martin on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 12 at 5:34 PM
ADC Therapeutics SA: ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business HighlightsADC Therapeutics SA: ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights
finanznachrichten.de - November 12 at 7:33 AM
Adc Therapeutics SA to Host Earnings CallAdc Therapeutics SA to Host Earnings Call
finance.yahoo.com - November 12 at 7:33 AM
ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business HighlightsADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights
finance.yahoo.com - November 12 at 7:33 AM
ADC Therapeutics (NYSE:ADCT) Trading Up 6.1%ADC Therapeutics (NYSE:ADCT) Trading Up 6.1%
americanbankingnews.com - November 11 at 8:03 PM
Is a Surprise Coming for ADC Therapeutics (ADCT) This Earnings Season?Is a Surprise Coming for ADC Therapeutics (ADCT) This Earnings Season?
finance.yahoo.com - November 11 at 3:23 PM
ADC Therapeutics (ADCT) to Release Earnings on ThursdayADC Therapeutics (ADCT) to Release Earnings on Thursday
americanbankingnews.com - November 6 at 1:50 PM
ADC Therapeutics (NYSE:ADCT) Trading 5.5% Higher ADC Therapeutics (NYSE:ADCT) Trading 5.5% Higher
americanbankingnews.com - November 4 at 8:42 PM
ADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual MeetingADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting
finance.yahoo.com - November 4 at 1:14 PM
ADC Therapeutics SAs Lock-Up Period To End  on November 11th (NYSE:ADCT)ADC Therapeutics SA's Lock-Up Period To End on November 11th (NYSE:ADCT)
americanbankingnews.com - November 4 at 1:10 AM
Early-stage study commences on ADC antibody-drug conjugate in solid tumorsEarly-stage study commences on ADC antibody-drug conjugate in solid tumors
seekingalpha.com - November 3 at 9:37 AM
ADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid TumorsADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors
finance.yahoo.com - November 3 at 9:37 AM
ADC therapeutics prices equity offeringADC therapeutics prices equity offering
seekingalpha.com - September 24 at 8:49 AM
ADC Therapeutics Announces Pricing of Public OfferingADC Therapeutics Announces Pricing of Public Offering
finance.yahoo.com - September 23 at 11:53 PM
ADC Therapeutics files U.S. application for lonca in blood cancerADC Therapeutics files U.S. application for lonca in blood cancer
seekingalpha.com - September 21 at 8:20 PM
ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large ...ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large ...
businesswire.com - September 21 at 8:20 PM
ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
finance.yahoo.com - September 21 at 8:20 PM
ADC Therapeutics Announces Proposed Public OfferingADC Therapeutics Announces Proposed Public Offering
finance.yahoo.com - September 21 at 8:20 PM
ADC Therapeutics Cami shows encouraging action in early-stage study in solid tumorsADC Therapeutics' Cami shows encouraging action in early-stage study in solid tumors
seekingalpha.com - September 17 at 1:09 PM
ADC Therapeuticss Cami shows encouraging action in early-stage study in solid tumorsADC Therapeutics's Cami shows encouraging action in early-stage study in solid tumors
seekingalpha.com - September 17 at 8:08 AM
ADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020ADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020
finance.yahoo.com - September 17 at 8:08 AM
ADC Therapeutics Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor CancersADC Therapeutics Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor Cancers
finance.yahoo.com - September 10 at 8:41 AM
ADC Therapeutics SAs (NYSE:ADCT) Profit OutlookADC Therapeutics SA's (NYSE:ADCT) Profit Outlook
finance.yahoo.com - August 20 at 11:28 PM
ADC Therapeutics SA's (NYSE:ADCT) Profit OutlookADC Therapeutics SA's (NYSE:ADCT) Profit Outlook
finance.yahoo.com - August 20 at 8:27 AM
57,225,93957,225,939
businesswire.com - August 19 at 10:27 PM
ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q2 2020 Results - Earnings Call TranscriptADC Therapeutics SA (ADCT) CEO Christopher Martin on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 18 at 11:15 PM
ADC Therapeutics SA: ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business HighlightsADC Therapeutics SA: ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights
finanznachrichten.de - August 18 at 7:58 AM
ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business HighlightsADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights
finance.yahoo.com - August 18 at 7:58 AM
ADC Therapeutics S.A.ADC Therapeutics S.A.
barrons.com - August 14 at 10:07 AM
ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020
finance.yahoo.com - August 12 at 6:58 PM
ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15thADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th
www.bloomberg.com - July 26 at 6:19 PM
Karyopharms XPOVIO Progress And Other News: The Good, Bad And Ugly Of BiopharmaKaryopharm's XPOVIO Progress And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - July 19 at 1:50 PM
Dosing underway in ADC Therapeutics LOTIS 3 combo trial in blood cancerDosing underway in ADC Therapeutics' LOTIS 3 combo trial in blood cancer
seekingalpha.com - July 17 at 9:34 AM
BRIEF-ADC Therapeutics Says U.S. FDA Lifts Partial Clinical Hold On Phase 2 Trial Of Camidanlumab TesirineBRIEF-ADC Therapeutics Says U.S. FDA Lifts Partial Clinical Hold On Phase 2 Trial Of Camidanlumab Tesirine
www.reuters.com - July 6 at 9:46 AM
ADC : FDA Lifts Partial Clinical Hold On Pivotal Phase 2 Trial Of Camidanlumab TesirineADC : FDA Lifts Partial Clinical Hold On Pivotal Phase 2 Trial Of Camidanlumab Tesirine
www.nasdaq.com - July 6 at 9:46 AM
FDA lifts partial hold on mid-stage study of ADC Therapeutics camidanlumab tesirineFDA lifts partial hold on mid-stage study of ADC Therapeutics' camidanlumab tesirine
seekingalpha.com - July 6 at 9:46 AM
FDA halts enrollment in mid-stage study of ADC Therapeutics camidanlumab tesirineFDA halts enrollment in mid-stage study of ADC Therapeutics' camidanlumab tesirine
seekingalpha.com - July 6 at 9:46 AM
New Ventures Portfolio Company, ADC Therapeutics, Completes $267 Million IPONew Ventures Portfolio Company, ADC Therapeutics, Completes $267 Million IPO
finance.yahoo.com - June 30 at 12:51 PM
ADCs lonca shows encouraging action in blood cancer studiesADC's lonca shows encouraging action in blood cancer studies
seekingalpha.com - June 12 at 3:13 PM
ADC conference call June 12 on loncastuximab tesirine dataADC conference call June 12 on loncastuximab tesirine data
seekingalpha.com - June 5 at 9:41 AM
ADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine (Lonca) Clinical Trial Data Being Presented at Virtual EHA Annual CongressADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine (Lonca) Clinical Trial Data Being Presented at Virtual EHA Annual Congress
finance.yahoo.com - June 5 at 9:41 AM
4Bio Capital: 4BIO Capital portfolio company ADC Therapeutics SA closes an upsized IPO of over $267.6 million4Bio Capital: 4BIO Capital portfolio company ADC Therapeutics SA closes an upsized IPO of over $267.6 million
www.finanznachrichten.de - May 20 at 8:37 AM
ADC Therapeutics Announces Closing of Upsized $267 Million Initial Public Offering and Receipt of the $65 Million First Tranche under Its $115 Million Convertible Credit ...ADC Therapeutics Announces Closing of Upsized $267 Million Initial Public Offering and Receipt of the $65 Million First Tranche under Its $115 Million Convertible Credit ...
www.businesswire.com - May 20 at 8:37 AM
ADC Therapeutics stock soars 56% in trading debutADC Therapeutics stock soars 56% in trading debut
finance.yahoo.com - May 20 at 8:37 AM
ADC Therapeutics Announces Closing of Upsized $267 Million Initial Public Offering and Receipt of the $65 Million First Tranche under Its $115 Million Convertible Credit Facility with DeerfieldADC Therapeutics Announces Closing of Upsized $267 Million Initial Public Offering and Receipt of the $65 Million First Tranche under Its $115 Million Convertible Credit Facility with Deerfield
finance.yahoo.com - May 20 at 8:37 AM
This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.